HC Wainwright Reiterates Buy Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)

Barinthus Biotherapeutics (NASDAQ:BRNS)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $3.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 203.03% from the company’s current price.

Barinthus Biotherapeutics Stock Down 2.0 %

Shares of NASDAQ:BRNS opened at $0.99 on Friday. Barinthus Biotherapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $4.16. The firm has a 50-day simple moving average of $1.01 and a 200 day simple moving average of $1.12. The company has a market cap of $39.83 million, a PE ratio of -0.66 and a beta of -0.80.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The company had revenue of $14.97 million for the quarter. As a group, research analysts forecast that Barinthus Biotherapeutics will post -1.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Gilead Sciences Inc. bought a new position in Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics comprises about 0.0% of Gilead Sciences Inc.’s investment portfolio, making the stock its 14th largest position. Gilead Sciences Inc. owned approximately 1.54% of Barinthus Biotherapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.